‘We Have a Job to Do’: Cancer Patients and Their Doctors Carry on with Clinical Trials During Covid-19
June 16, 2020
(STAT News) – Around the world, Covid-19 has disrupted all types of clinical trials, decreasing by 74% the number of new patients enrolling. In cancer, the number of new patients entering Phase 2 and 3 cancer trials in the U.S. plummeted by about 46% to 48% in the last two weeks of March, said Margaret Mooney, associate director of the Cancer Therapy Evaluation Program in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. By the last week of May and first week of June, the cliff wasn’t so steep, moderating to a 25% to 30% decline.